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Abstract
Background: Renal cell carcinoma can cause various paraneoplastic syndromes including metabolic and
hematologic disturbances. Paraneoplastic hypereosinophilia has been reported in a variety of hematologic and
solid tumors. We present the first case in the literature of severe paraneoplastic hypereosinophilia in a patient with
renal cell carcinoma.
Case presentation: A 46 year-old patient patient with a history of significant weight loss, reduced general state of
health and coughing underwent radical nephrectomy for metastasized renal cell carcinoma. Three weeks after
surgery, the patient presented with excessive peripheral hypereosinophilia leading to profound neurological
symptoms due to cerebral microinfarction. Systemic treatment with prednisolone, hydroxyurea, vincristine,
cytarabine, temsirolimus and sunitinib led to reduction of peripheral eosinophils but could not prevent rapid
disease progression of the patient. At time of severe leukocytosis, a considerable increase of cytokines associated
with hypereosinophilia was measurable.
Conclusions: Paraneoplastic hypereosinophilia in patients with renal cell carcinoma might indicate poor prognosis
and rapid disease progression. Myelosuppressive therapy is required in symptomatic patients.
Keywords: Paraneoplastic, Hypereosinophilia, Leukocytosis, Renal cell carcinoma, Leukemoid reaction,
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Background
Renal cell carcinoma can cause various paraneoplastic
syndromes such as hypercalcemia, hypertension and
ectopic hormone production [1]. Renal cell carcinoma
can also provoke hematologic disturbances such as poly-
cythemia due to an increased production of erythropoie-
tin [2]. Hypereosinophilia has been reported as a
paraneoplastic syndrome in several solid and hematolo-
gical malignancies. We report the first case of severe
paraneoplastic hypereosinophilia with cerebral infarction
in a patient with metastatic renal cell carcinoma.
Case Presentation
Case presentation and management
A 46 year-old patient with no relevant diseases in past
medical history had a history of significant weight loss,
reduced general state of health and coughing. A whole
body CT revealed a hypervascularized renal tumor with
a level I tumor thrombus [3] (Figure 1) and multiple
pulmonary lesions. At the time of primary diagnosis,
blood analysis showed a WBC of 19,550/μl (4,000-7,000/
μl) with 16% (0-6%) of eosinophilic granulocytes. The
patient was admitted to our hospital 7 days after pri-
mary diagnosis (day 7) for radical nephrectomy, partial
hepatectomy and reconstruction of the inferior vena
cava. The intra- and postoperative course was unevent-
ful. Histological examination showed clear cell renal cell
carcinoma with sarcomatoid components (Tumor stage:
pT4, pNx, M1, L0, V1, Rx, G3). According the MSKCC
criteria, the patient was intermediate risk at time of
diagnosis [4]. In an intersciplinary tumor board, the
patient was recommended to begin with oral sunitinib.
The patient was discharged from hospital 7 days after
surgery (day 14) with a WBC of 14,360/μl. On day 29
the patient again presented at our hospital in a reduced
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Laboratory examination demonstrated leukocytosis of 37
×1 0
3/μl with 34.2% of eosinophilic granulocytes. Ultra-
sound revealed a partially liquid mass with 10 × 5 cm of
size, which was suspicious of abscess formation, con-
firmed by computed tomography. The liquid mass was
subsequently drained and 700 mL of serous fluid could
be evacuated. Cultures of the fluid remained sterile. The
patient was treated with intravenous antibiotics (vanco-
mycine, tazobactam/piperacilline, and ciprofloxacin).
However, leukocytes and eosinophilic granulocytes
increased further despite antibiotic therapy and
drainage.
On day 33, the patient presented with a weakness of
the left arm. Multiple fresh embolic lesions were
detected by MRI (magnetic resonance tomography) in
the parietal, temporal and occipital lobes bilaterally (Fig-
ure 2). Furthermore a small infarction was detected in
the cerebellum which led to the suspicion of cardiac
emboli. Transthoracal echocardiography showed a pro-
foundly decreased function of the left ventricle with
inferior hypokinesia, a low-grade mitral valve insuffi-
ciency and no evidence of structures characteristic for
endocarditis. The corresponding electrocardiogram
showed a sinus tachycardia with ventricular extrasystoles
(Lown classification 2). Ultrasound of extracranial ves-
sels did not show significant stenosis. As at this point
leukocytes had further increased up to 57,390/μlw i t h
37.7% of eosinophilic granulocytes (Figures 3 and 4).
Several tests were performed to rule out non-cancer
causes of hypereosinophilia such as parasitic infections,
allergy (including determination of serum mast cell tryp-
tase), hypereosinophilic syndrome due to FIP1L1/
PDGFR receptor mutations and aberrant lymphocytes
(no CD4-positive CD3-negative lymphocytes characteris-
tic for lymphoproliferative hypereosinophilic syndrome),
which remained all negative. Consequently, the patient
was submitted to the department of medical oncology
and received steroids and cytoreductive therapy with
hydroxyurea. Doses of hydroxyurea and prednisone were
increased stepwise up to 3 g/day and 100 mg/day,
respectively. Moreover, the patient received vincristine
once (2 mg) and 2 doses of cytarabine (2 × 150 mg/24
h) as cytoreductive therapy of symptomatic hypereosino-
philia (Figure 3).
A CT performed 2 weeks after the drainage of the
fluid collection showed a massive progression of the ret-
roperitoneal tumor mass in the surgical bed (Figure 5).
Progress of the pleural and pulmonary metastases could
be observed as well. Systemic therapy with temsirolimus
(25 mg/once a week) was initiated, as at this point, swal-
lowing difficulties (leading to parental nutrition) did not
permit oral therapy with sunitinib. This led to a short-
term response of pulmonary and pleural manifestations
(according to RECIST). The retroperitoneal tumor mass
also responded to temsirolimus with tumor necrosis.
However, a CT performed one month after initiation of
temsirolimus therapy revealed a progressive disease of
local relapse with hepatic, pancreatic and diaphragmatic
invasion.
Administration of antiproliferative drugs for treatment
of hypereosinophilia (cytarabine, hydroxyurea and vin-
cristin) and renal cell carcinoma led to significant reduc-
tion of leukocytes and eosinophils as well as
pancytopenia (Figure 3).
We performed a multiplex cytokine assay based on
Luminex
R technology (Progen
R)t od e t e r m i n el e v e l so f
multiple cytokines of serums drawn on day 44 (>
200.000 leukocytes/μl) and day 74 (8,580 leukocytes/μl).
On day 44, we found severely increased concentrations
of multiple cytokines and their receptors including
b F G F ,G - C S F ,G M - C S F ,H G F ,I L 2 - R A ,M C P - 1a n d
MIP-1b. Results are shown in Table 1.
As swallowing difficulties disappeared, according to
his will the patient was set on sunitinib 50 mg/d two
months after nephrectomy. The patient could be dis-
charged from hospital in reduced general condition 11
weeks after nephrectomy. Due to further disease pro-
gression, the patient died 4 months after primary
diagnosis.
Discussion
Hypereosinophilia is most commonly associated with
allergy and parasitic infections. Furthermore, several
drugs, pulmonary and gastrointestinal diseases have
Figure 1 Preoperative imaging showing a hypervascularized
renal tumor with a level I tumor thrombus in the vena cava.
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Figure 2 A: axial FLAIR image shows multifocal cortical and subcortical hyperintense lesions (arrows) presumed to be of embolic
origin. B and 2 C: axial diffusion-weighted image-DWI (b-value, 1,000 s/mm
2) (Figure 2B) and corresponding apparent diffusion coefficient (ADC)
map demonstrate marked water diffusion restriction in acute embolic ischemia (arrows). Note the drop in signal intensity on ADC-map (Figure
2C, arrows).
Figure 3 Leukocytes and eosinophilic granulocytes count. Lower bars show doses of applicated drugs.
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lia [8,9]. Within recent years, a couple of molecular
alterations have been identified to account for malignant
hypereosinophilic syndromes including rearrangements
of the PDGFR receptor [8]. A mild to moderate increase
(> 500/μl to < 1,500/μl) of eosinophils can be found in
up to 5% of patients with malignancies [10]. Severe per-
ipheral hypereosinophilia (> 5,000/μl) has been
described in a variety of hematologic and solid tumors
including gastrointestinal tumors [11,12], bronchial car-
cinoma [10], sarcomas [13] and prostate cancer [14].
Several cytokines produced by the primary tumor have
been identified to account for increased production of
eosinophilic granulocytes in the bone marrow including
interleukin-3, interleukin-5 and GM-CSF (granulocytes
macrophages stimulating factor) [12,15,16]. Other
mechanisms for hypereosinophilia in patients with
malignancy include an eosinophilotactic response due to
necrosis in the tumor and increased production of eosi-
nophils due to tumor cell dissemination in the bone
marrow [9]. In the case presented here, we found
increase of multiple cytokines at the time of massive
leukocytosis and hypereosinophilia. G-CSF and GM-CSF
which may be secreted by tumor cells and induce pro-
duction of eosinophils [17,18] were significantly ele-
vated. Soluble receptor of interleukin 2 (IL2-RA) has
been shown to be an important mediator of autocrine
and paracrine regulation of eosinophils [19]. MIP-1a
which is secreted by eosinophils and induces further
leukocyte activation was also significantly elevated [20].
Both, elevation of interleukin 8 and MCP-1, may be
Figure 4 Peripheral blood smear hypereosinophilia with hypersegmented forms.
Figure 5 Progression of retroperitoneal tumor mass after
radical nephrectomy within 4 weeks (coronal CT-images).
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[21]. All these cytokines were significantly lower at time
of normal leukocyte count. However, it is not possible
to define the exact mechanism of hypereosinophilia in
this patient, as the source of the cytokines remained
undefined and mediators causing hypereosinophilia may
also be induced by eosinophils themselves. The tumor
presented with extensive necrotic areas showing massive
infiltration of eosinophils (Figure 6). Tumor necrosis has
been discussed as a factor promoting tumor related
hypereosinophila [22]. However, as a steady increase of
leukocytes was observed after resection of the tumor
with necrotic areas, tumor necrosis cannot be regarded
as the only promoter of increasing eosinophils in the
present case and other sources for cytokines promoting
hypereosinophilia are probable.
Paraneolastic eosinophilia is usually mild without any
clinical symptoms, but absolute counts may occasionally
exceed 25,000/μl and may cause end-organ damage. In a
few reported cases of paraneoplastic hypereosinophilia,
neurological symptoms occurred due to thromboem-
bolic events with multiple infarctions [23,24,14]. Signifi-
cantly reduced left ventricular function in our patient
may be interpreted as end-organ damage as well.
Several studies have shown that paraneoplastic eosino-
philia is a poor prognostic sign and indicates metastatic
and extensive disease [25,26]. In a series of 36 cases
Table 1 Levels of multiple cytokines at time of excessive
leukocytosis (day 44) and after administration of
cytoreductive drugs) (day 74) measured by ultiplex
cytokine testing (Progen)
Cytokine Unit Reference Day 44 Day 74
EGF pg/ml -780 201 15,8
Eotaxin pg/ml 175.8 ± 49.3 20,4 11,6
FGF-Basic pg/ml 1,5-6,0 40,8 23,5
G-CSF pg/ml 27.34 ± 8.00 93,5 < LOW >
GM-CSF pg/ml -2,3 40,6 19,8
HGF pg/ml 120 ± 120 < HIGH > 4480
IFN-a pg/ml 16.8 ± 6.59 25,3 < LOW >
IFNy pg/ml < LOW > < LOW >
IL-10 pg/ml 9.2 ± 1.5 19,3 15,8
IL-12 p40/p70 pg/ml 171.1 ± 6,25 104 52,6
IL-13 pg/ml 25.5 ± 2.94 35,7 < LOW >
IL-15 pg/ml 16.2 ± 4.0 < LOW > 45,2
IL-17 pg/ml 0-127 28,8 23,6
IL-1b pg/ml 40.2 ± 8.78 25,7 12,5
IL-1RA pg/ml 189 ± 22 979 241
IL-2 pg/ml 2.4 ± 0.8 9,16 6,01
IL-2R pg/ml 426.5 ± 22.4 12300 18300
IL-4 pg/ml 3.34 ± 0.84 35,8 < LOW >
IL-5 pg/ml < LOW > < LOW >
IL-6 pg/ml 22.8 ± 7 330 299
IL-7 pg/ml 66,4 47
IL-8 pg/ml 9.56 ± 0.4 652 111
IP-10 pg/ml 4.5-27.1 73,6 27,3
MCP-1 pg/ml 173.2 ± 15.04 1110 377
MIG pg/ml 22.1-52.4 < LOW > < LOW >
MIP-1a pg/ml 88.1 ± 14.31 179 45,8
MIP-1b pg/ml 135.1 ± 29.22 2640 278
RANTES pg/ml 1100-4360 3750 664
TNFa pg/ml 34.32 ± 11.46 9,21 5,81
VEGF pg/ml 76.6 ± 6.07 65,5 24,1
Low = concentration below detection limit, High = above detection limit.
Reference values were obtained from [5-7]
Figure 6 A and B: Resection specimen of the right kidney and
adrenal gland reveals a poorly, in parts sarcomatoid
differentiated renal carcinoma. Gross examination shows
infiltration of the adenal gland, renal plevis and macroscopic
vascular invasion. A: (H&E, 200×) Spindle like shaped tumor cells
with small eosiniphilic cytoplasmn and pleomophic nuclei with
eosinophilic nucleoli. Interspersed small amounts of histiocytes and
small lymphocytes. The amount of eosinophils is not elevated in
viable tumor areas. B: (H&E, 400×): Areas of tumor necrosis withs
rims of histiocytes and increased number of eosinophils.
Todenhöfer et al. BMC Urology 2012, 12:7
http://www.biomedcentral.com/1471-2490/12/7
Page 5 of 7with paraneoplastic hypereosinophilia, 32 patients had
metastatic disease [27]. The patient reported here had a
disseminated disease with pulmonary and bone metas-
tases and presented with extraordinary rapid disease
progression with poor response to surgical and systemic
treatment. In previously reported cases, peripheral eosi-
nophil count correlated with disease activity [28]. We
could not find a clear correlation between tumor mass
and absolute granulocyte count in the reported patient.
Symptomatic paraneoplastic eosinophilia could be
treated with drugs leading to decreased production and
function of eosinophilic granulocytes including gluco-
corticoids, hydroxyurea, vincristine [29,30]. Furthermore,
reduction of tumor mass either by surgery or systemic
treatment has been shown to reduce peripheral eosino-
philic counts in paraneoplastic hypereosinophilia [11,28].
In the present case, a combination of drugs directly
targeting function and production of granulocytes (pre-
dnisone, hydroxyurea, vincristin, cytarabine) and drugs
targeting renal carcinoma (sunitinib and temsirolimus)
led to a decrease of absolute leukocytes and eosinophils.
Neurologic impairment and general status significantly
improved with reduced numbers of eosonophilic granu-
locytes. First line sunitinib had to be temporarily
replaced by temsirolimus, as swallowing difficulties did
not permit oral therapy. Temsirolimus led to a short-
term response (according to RECIST) 2 weeks after
initiation. However, rapid progression was observed only
4 weeks after initiation of systemic therapy. As reduc-
tion of prednisone led to significant hypereosinophilia-
associated reduction of vigilance with prompt improve-
ment after increase of dosage we consider prednisone as
a mainstay of the therapeutic approach. Hence, it leads
to reduced eosinophilic count and improvement of
hypereosinophilia associated symptoms.
Conclusions
This is the first reported case in the literature of exces-
sive paraneoplastic hypereosinophilia in a patient with
metastatic renal cell carcinoma. Paraneoplastic hypereo-
sinophilia due to renal cell carcinoma might indicate
poor prognosis and rapid disease progression. Myelo-
suppressive therapy is required in symptomatic patients.
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